LA JOLLA, CALIFORNIA / August 29, 2023 / GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells, today announced it has engaged B2i Digital, Inc. (“B2i”) to execute an innovative digital engagement and awareness program. B2i brings together decades of experience from public relations, investment banking, and digital marketing to advise on and develop marketing campaigns to target appropriate stakeholders.
As part of the targeted campaign, B2i will harness its platform and data-driven digital marketing expertise to highlight GRI Bio's differentiated pipeline of NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
"As we work toward major catalysts, we want our story to reach new and valuable audiences," said GRI Bio CEO Marc Hertz, Ph.D. "B2i Digital's cutting-edge digital technologies will allow us to communicate our progress, competitive advantages, and long-term vision to stakeholders."
"We are proud to partner with GRI Bio as they pioneer novel immunotherapies leveraging NKT cell biology," added David Shapiro, B2i Digital CEO. "From a deep pipeline to an extensive compound library, GRI Bio is delivering on its mission to develop transformative NKT cell-targeted medicines. We look forward to leveraging the full power of our digital toolset to showcase and expand GRI Bio’s stakeholder base and visibility to our 410,000+ social media community."
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story. B2i Digital creates robust profiles for companies on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant stakeholders information about each company based on its sector, stage in its capital markets evolution, and overall company story. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its awareness platform, M-Vest.com.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing how inflammatory, fibrotic, and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are vital regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for treating idiopathic pulmonary fibrosis, a serious disease with significant unmet needs. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s and B2i Digital’s expectations with respect to development and commercialization of the Company’s product candidates, the initiation or completion of clinical trials, the potential benefits, impact, and competitive advantage of the Company’s product candidates, any estimate or implication as to potential market size or potential revenue, any reference to potential catalyst achievements, which may or may not be achieved, paid or received in the future, and the potential benefits of B2i Digital’s campaigns or other services. Actual results may differ from the forward-looking statements expressed by the Company or Aardvark in this press release, and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for their respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company or Aardvark to compete with other companies currently marketing or engaged in the development of products and services that the Company or Aardvark are currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the success or failure of any digital marketing campaign to benefit the Company or its stockholders; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on February 24, 2023 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
No Offer or Solicitation
This press release will not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
